- Home
- MFIN vs RNAC Comparison
MFIN vs RNAC Comparison
Compare MFIN & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFIN | RNAC |
|---|---|---|
| Founded | 1995 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.3M | 204.6M |
| IPO Year | 1996 | 2016 |
Fundamental Metrics
Financial Performance| Metric | MFIN | RNAC |
|---|---|---|
| Price | $10.65 | $8.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $38.40 |
| AVG Volume (30 Days) | 43.3K | ★ 192.2K |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | ★ 1.06 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $338,783,000.00 | $1,091,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.83 | N/A |
| P/E Ratio | $6.12 | ★ N/A |
| Revenue Growth | ★ 15.53 | N/A |
| 52 Week Low | $7.71 | $5.98 |
| 52 Week High | $10.98 | $23.93 |
Technical Indicators
Market Signals| Indicator | MFIN | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 61.06 |
| Support Level | $9.96 | $6.66 |
| Resistance Level | $10.39 | $8.40 |
| Average True Range (ATR) | 0.31 | 0.54 |
| MACD | 0.08 | 0.22 |
| Stochastic Oscillator | 87.87 | 87.10 |
Price Performance
Historical ComparisonAbout MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.